Daily News Podcast

Rivaroxaban data abound at ESC 2018

Publish date: August 28, 2018

 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Mobile contraception app gets FDA approval
MDedge Hematology and Oncology
Variation doesn’t mean quality when it comes to diet
MDedge Hematology and Oncology
Medicare Advantage pushback
MDedge Hematology and Oncology
Cardiovascular risk management supported for type 2 diabetes
MDedge Hematology and Oncology
An epidemic of non-alcoholic fatty liver disease
MDedge Hematology and Oncology
Sleepio app tied to reducing insomnia, depression
MDedge Hematology and Oncology
5 digital HIPAA myths
MDedge Hematology and Oncology
Screen for cervical cancer based on age, risk
MDedge Hematology and Oncology
Is it time for PCPs to take over chronic HCV?
MDedge Hematology and Oncology
Lorcaserin shows cardiovascular safety
MDedge Hematology and Oncology